Novavax shares are trading higher after the FDA advisory committee voted to recommend updated vaccines for JN.1-lineage composition. Novavax expects to be ready for delivery in September, pending authorization.
Portfolio Pulse from Benzinga Newsdesk
Novavax shares are trading higher following an FDA advisory committee's recommendation for updated JN.1-lineage vaccines. Novavax aims to deliver the vaccines by September, pending authorization.
June 06, 2024 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax shares are experiencing an uptick after the FDA advisory committee recommended updated JN.1-lineage vaccines. The company plans to deliver these vaccines by September, pending final authorization.
The FDA advisory committee's recommendation is a significant regulatory milestone for Novavax. The anticipation of delivering the updated vaccines by September, pending authorization, has positively impacted the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100